On August 12, 2024, Femasys Inc., a biomedical company specializing in women's health, reported its financial results for the quarter ending September 30, 2024, and provided a corporate update. The company, listed on NASDAQ under the symbol FEMY, announced significant commercial progress, including partnerships in the U.S. and Europe, particularly with Boston IVF and the launch of FemaSeed in California and Florida. Femasys also reported strategic distribution partnerships in Spain for its CE-marked products, which are expected to generate over $1.3 million in the next year. The company received FDA 510(k) clearance for FemChec and Health Canada approval for FemVue MINI. A new U.S. patent was issued for the FemBloc device. Financially, Femasys saw a 127.1% increase in sales to $554,908 in Q3 2024 compared...Show More

On August 12, 2024, Femasys Inc., a biomedical company specializing in women's health, reported its financial results for the quarter ending September 30, 2024, and provided a corporate update. The company, listed on NASDAQ under the symbol FEMY, announced significant commercial progress, including partnerships in the U.S. and Europe, particularly with Boston IVF and the launch of FemaSeed in California and Florida. Femasys also reported strategic distribution partnerships in Spain for its CE-marked products, which are expected to generate over $1.3 million in the next year. The company received FDA 510(k) clearance for FemChec and Health Canada approval for FemVue MINI. A new U.S. patent was issued for the FemBloc device. Financially, Femasys saw a 127.1% increase in sales to $554,908 in Q3 2024 compared to the same period in 2023. R&D expenses rose by 11.1%, and the net loss for the quarter was $5.4 million, an increase from the previous year. The company's cash and cash equivalents stood at $7.6 million, with an accumulated deficit of $122.1 million. Femasys expects its current funds to sustain operations into July 2025. The full financial details are available in the company's Form 10-Q filed on November 12, 2024.